Strategies to extend plasma half-lives of recombinant antibodies
- PMID: 19489651
- DOI: 10.2165/00063030-200923020-00003
Strategies to extend plasma half-lives of recombinant antibodies
Abstract
Recombinant antibodies, including whole antibodies, antibody fragments, antibody fusion proteins or conjugates, and more recently also small antibody mimetics, have found increasing applications as therapeutics, e.g. for the treatment of cancer or inflammatory diseases. While whole antibodies have an exceptionally long half-life, small antibody derivatives often suffer from rapid elimination from the circulation. In order to improve administration and therapeutic efficacy, modifications to extend the plasma half-life have been developed and implemented in these antibody formats. This review provides a comprehensive summary of the various strategies currently available to extend plasma half-lives of recombinant antibodies.
Similar articles
-
Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18. J Immunol. 2010. PMID: 20083659
-
Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review.Int J Biol Macromol. 2018 Nov;119:306-311. doi: 10.1016/j.ijbiomac.2018.07.141. Epub 2018 Jul 21. Int J Biol Macromol. 2018. PMID: 30041038 Review.
-
SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.Protein Eng Des Sel. 2010 Apr;23(4):195-202. doi: 10.1093/protein/gzp094. Epub 2010 Feb 4. Protein Eng Des Sel. 2010. PMID: 20299542
-
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9. J Drug Target. 2014. PMID: 24404896 Review.
-
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17. Methods. 2014. PMID: 23872058
Cited by
-
Active immunoprophylaxis with a synthetic DNA-encoded monoclonal anti-respiratory syncytial virus scFv-Fc fusion protein confers protection against infection and durable activity.Hum Vaccin Immunother. 2020 Sep 1;16(9):2165-2175. doi: 10.1080/21645515.2020.1748979. Epub 2020 Jun 16. Hum Vaccin Immunother. 2020. PMID: 32544376 Free PMC article.
-
Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains.J Biol Chem. 2012 Feb 10;287(7):4462-9. doi: 10.1074/jbc.M111.311522. Epub 2011 Dec 6. J Biol Chem. 2012. PMID: 22147690 Free PMC article.
-
Access to site-specific Fc-cRGD peptide conjugates through streamlined expressed protein ligation.Org Biomol Chem. 2016 Oct 12;14(40):9549-9553. doi: 10.1039/c6ob01833e. Org Biomol Chem. 2016. PMID: 27722696 Free PMC article.
-
Candidate antibody-based therapeutics against HIV-1.BioDrugs. 2012 Jun 1;26(3):143-62. doi: 10.2165/11631400-000000000-00000. BioDrugs. 2012. PMID: 22462520 Free PMC article. Review.
-
Development of ZHPV16E7- granzyme B immunoaffitoxin: dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death.Front Immunol. 2025 Jul 21;16:1616715. doi: 10.3389/fimmu.2025.1616715. eCollection 2025. Front Immunol. 2025. PMID: 40761801 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources